A forum of prominent industry stakeholders highlights the challenges for patients in navigating the multiple legal, regulatory, and ethical barriers to cross-border participation.
How simulation can help in the planning and implementation of adaptive clinical trials.
What do the G8 Summit, national security, and the pharmaceutical industry have in common?
Our training places heavy emphasis on site selection: The entire study may suffer if sites are chosen poorly.
The clinical trial industry has a rare opportunity to redefine its role in public health conversations.
Three profiled companies have three different needs when it comes to choosing PDA.
I've recently reviewed many articles on subject recruitment, retention, and attrition in clinical trials. I have found the same three basic research methods: surveys (by telephone and in person), interviews, and focus groups. The information gathered from the three methods include demographics, willingness to participate, problems experienced in clinical trials, motivations for volunteering, health behaviors, social support, benefit expectations, and understanding of the research project. But such strategies collect only the most superficial data, so we don't know nearly as much about the clinical trial experience as we need to know.
The United States and Europe host most clinical trials?and receive the benefits of drugs even when such trials are carried out in developing countries. Eager to correct an imbalance, Mexico wants to participate more extensively. Is it ready?
A key function in clinical trials, patient enrollment, has fallen behind during a time where technology has played a vital role in the industry. Adaptive patient recruitment allows for clinical data to be collected and reviewed in real-time as to improve enrollment outcomes as they are taking place.
Both parties benefit from intentional friendships, and nowadays CRAs are key to this cordial effort.
A new reference guide clarifies uncertainty surrounding this sometimes misunderstood document.
Partnership agreements for CROs and eClinical technology providers can be as beneficial as sponsor/CRO partnerships.
The CRO industry is on a course for continued rapid growth with the rise of genetics and genomics, as well as the push toward partnering and more postapproval research.
A new reference guide clarifies uncertainty surrounding this sometimes misunderstood document.
eClinical Trials: Planning & Implementation is a useful resource for those new to the industry as well as practitioners already involved in planning and implementing eClinical trials.
The idea is great: when an investigator submits a grant to any NIH institute, if the study will involve more that one performance site, the grant must include a plan to rely on one single IRB.
Expert outlines approaches to preventing fraud in clinical research-a more prevalent problem that many believe.
Interactive voice response systems are commonly used in clinical trials to manage the flow of trial medication supplies to sites and to manage the allocation of these supplies to individual subjects. Other advantages and uses include access to real-time information for trial managers, collection of diary card data directly from subjects, and as an aid to subject recruitment.1
More than 1000 contract research organizations exist worldwide, and the number is growing. CROs differ widely in size and profile. Before a project can be contracted out, sponsors often spend valuable time searching for the CRO that best fits the project's specifications. Consultants are often needed to help hew a path through this jungle, a task made all the more difficult by the intentional withholding of information that would help sponsors decide. The World Wide Web would be an excellent means for CROs to communicate relevant and fluid information about their companies, and herein I offer a model for CROs to use.
How applying statistics to the design, conduct, and analysis of Phase I trials can improve clinical research.
In the biomedical research industry, and at Pfizer in particular, we are committed to what we call "The Three As"-making medicines available, accessible, and affordable.
As the number and complexity of clinical trials grows-lengthening clinical trial durations and raising costs-sponsors and CROs need a way to streamline trial management, shorten study durations, and reduce expenditures. Customer relationship management (CRM) strategies update the paper-intensive methods of the past and offer an innovative approach to managing clinical trials-an approach that focuses on strengthening relationships between trial participants, especially investigators and subjects.
A new reference guide clarifies uncertainty surrounding this sometimes misunderstood document.
Real examples from recent studies illustrate the risks associated with making such a delicate decision.
Following the examples of these six companies might change your organization for good.
Streamlining electronic clinical outcome assessment and patient-reported outcome processes can aid in decreasing timelines.